Alanood Abdulrhman Almusaiteer

Alanood Abdulrhman Almusaiteer


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
AAAlanoud Alomair
Alanoud Alomair
AAAlanood Abdulrhman Almusaiteer
Alanood Abdulrhman Almusaiteer
RAReem Mohammed Ababtain
Reem Mohammed Ababtain
SASara Essa Alotaibi
Sara Essa Alotaibi
RARana Hrimal Alotibi
Rana Hrimal Alotibi
DADeema Munif Alotaibi
Deema Munif Alotaibi
Background: Biologic therapies have improved outcomes in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), but reliable biomarkers predicting treatment response remain unclear. This systematic review and meta-analysis evaluated predictive biomarkers associated with response to biologic therapy. Methods: A systematic review of randomized controlled trials and observational studies evaluating biomarkers of response to biologic therapy in severe uncontrolled CRSwNP was conducted. Data were extracted using a standardized form, and quantitative synthesis was performed where appropriate. Risk of bias was assessed using the Cochrane risk-of-bias 2 tool and the Newcastle–Ottawa Scale. Results: The most frequently investigated predictors of treatment response included blood eosinophil count, serum IgE, tissue eosinophilia, FeNO, and clinical characteristics such as comorbid asthma and NSAID-exacerbated respiratory disease (NSAID-ERD). Biologic therapy consistently improved clinical outcomes; however, evidence supporting any single biomarker as a reliable predictor of treatment response remained inconsistent because of substantial heterogeneity across studies. Conclusions: Current evidence does not support a universally validated predictive biomarker for biologic response in severe uncontrolled CRSwNP. Further standardized, prospective studies are needed to enable personalized biologic therapy.